Penumbra, Inc. (NYSE:PEN - Get Free Report) EVP Johanna Roberts sold 600 shares of the company's stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $300.01, for a total value of $180,006.00. Following the completion of the transaction, the executive vice president now directly owns 66,159 shares in the company, valued at approximately $19,848,361.59. The trade was a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Johanna Roberts also recently made the following trade(s):
- On Tuesday, April 1st, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $269.11, for a total transaction of $161,466.00.
- On Monday, March 3rd, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $287.43, for a total transaction of $172,458.00.
Penumbra Trading Up 0.8 %
Penumbra stock opened at $300.50 on Friday. The firm has a 50-day moving average price of $276.99 and a two-hundred day moving average price of $254.39. The firm has a market capitalization of $11.62 billion, a price-to-earnings ratio of 883.82, a PEG ratio of 2.83 and a beta of 0.56. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02.
Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.17. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The company had revenue of $324.14 million during the quarter, compared to analyst estimates of $315.72 million. Sell-side analysts expect that Penumbra, Inc. will post 3.67 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. UMB Bank n.a. grew its holdings in shares of Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $46,000 after acquiring an additional 70 shares during the last quarter. Hurley Capital LLC purchased a new position in Penumbra in the 4th quarter worth about $56,000. Huntington National Bank increased its stake in Penumbra by 138.7% in the 4th quarter. Huntington National Bank now owns 265 shares of the company's stock worth $63,000 after purchasing an additional 154 shares in the last quarter. Mather Group LLC. raised its holdings in Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company's stock worth $73,000 after buying an additional 208 shares during the period. Finally, Versant Capital Management Inc lifted its stake in Penumbra by 893.5% during the first quarter. Versant Capital Management Inc now owns 308 shares of the company's stock valued at $82,000 after buying an additional 277 shares in the last quarter. Institutional investors own 88.88% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the stock. StockNews.com raised shares of Penumbra from a "hold" rating to a "buy" rating in a research report on Thursday. Stifel Nicolaus set a $318.00 price objective on Penumbra and gave the company a "buy" rating in a research note on Thursday. UBS Group reiterated a "buy" rating and issued a $330.00 target price (up previously from $320.00) on shares of Penumbra in a research report on Thursday. Piper Sandler reiterated an "overweight" rating and issued a $330.00 price target (up from $250.00) on shares of Penumbra in a report on Wednesday, February 19th. Finally, BTIG Research restated a "buy" rating on shares of Penumbra in a research note on Thursday. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $302.40.
Get Our Latest Research Report on Penumbra
Penumbra Company Profile
(
Get Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
